(Q37987435)

26 August 2017

title

Ezetimibe--a new approach in hypercholesterolemia management (English)

1 reference

26 August 2017

0 references

Bogusław Okopień

4

0 references

Krzysztof Łabuzek

series ordinal

2

object named as

Krzysztof Łabuzek

1 reference

26 August 2017

3

Antoni Stadnicki

1 reference

26 August 2017

1

Dariusz Suchy

1 reference

26 August 2017

publication date

1 January 2011

1 reference

26 August 2017

published in

Pharmacological Reports

1 reference

26 August 2017

volume

63

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

1335-1348

1 reference

Impact of ezetimibe on atherosclerosis: is the jury still out?

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Treatment of hyperlipidemia in cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

The complexities of hepatic drug transport: current knowledge and emerging concepts.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

The discovery of ezetimibe: a view from outside the receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

New options in the treatment of lipid disorders in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe: a novel option for lowering cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe and cancer--an uncertain association

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Update on dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Familial hypercholesterolemia—Improving treatment and meeting guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

New medications which decrease levothyroxine absorption

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Simvastatin with or without ezetimibe in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Pharmacodynamic interaction between ezetimibe and rosuvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimib influences the expression of raft-associated antigens in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetim

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Analyses of cancer data from three ezetimibe trials

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients invitro

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

RETRACTED: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe is an inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Use of ezetimibe during HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

T-cell depletion eliminates the development of cardiac allograft vasculopathy in mice rendered tolerant by the induction of mixed chimerism

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970698-3

7 January 2021

10.1016/S1734-1140(11)70698-3

Identifiers

DOI

1 reference

26 August 2017

1 reference